Skip to main content

Table 1 Patients’ baseline characteristics stratified by treatment assignment. Data are expressed as mean (SD), unless otherwise specified

From: Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

  FEIBA
n = 6
Placebo
n = 6
Age, years 62.5 (4.3) 49.2 (13.1)
Gender, n (% female) 4 (67) 0 (0)
Weight, kg 101 (20.0) 84 (9.5)
Height, cm 175 (7.6) 180 (8.4)
Body mass index, kg/cm2 33 (5.0) 26 (4.4)
Non-Hispanic, n (%) 6 (100) 5 (83)
Diabetes, n (%) 0 (0) 1 (17)
Hypertension, n (%) 6 (100) 3 (50)
Smoking status, n (%) 3 (50) 2 (33)
CVA, n (%) 2 (33) 0 (0)
Anti-platelet therapy, n (%) 4 (67) 2 (33)
ASA score ≥ 4, n (%) 6 (100) 4 (67)
Baseline labs
 BUN 20 (9.4) 19 (2.8)
 Creatinine (mg/dL) 0.89 (0.3) 1.13 (0.2)
 Hematocrit (%) 39 (1.7) 43 (2.5)
 Platelet count (K/cu) 203 (62) 194 (16)
 aPTT 44 (34) 27 (3)
 INR 1.05 (0.1) 1.01 (0)
 Fibrinogen (mg/dL) 403 (63) 337 (100)
  1. FEIBA, factor eight inhibitor bypass activity; CVA, cerebrovascular accident; ASA, American Society of Anesthesiology physical status; BUN, blood urea nitrogen; aPTT, activated partial thromboplastin time; INR, international normalized ratio